论文部分内容阅读
目的观察硫普罗宁钠联合还原型谷胱甘肽对原发性肝癌肝动脉化疗栓塞(TACE)后肝损害的治疗效果。方法选择2014年3~12月医院收治的因原发性肝癌行TACE术后肝损伤患者68例,随机分为治疗组与对照组各34例。治疗组采用硫普罗宁钠联合还原型谷胱甘肽治疗,对照组采用葡醛内酯、肌苷等治疗,观察2组临床疗效,治疗前、后肝功能及不良反应。结果治疗后2组肝功能指标(ALT、AST、TBi L)均有明显改善(P<0.05),且治疗组各项指标均优于对照组,差异有统计学意义(P<0.05)。治疗组总有效率91.2%明显优于对照组的65.7%,差异有统计学意义(P<0.05)。2组均出现TEAC术后不良反应,如疲乏、恶心、呕吐、肝区疼痛、低热、白细胞减少等,但治疗组上述症状改善较对照组明显。2组治疗期间均未出现其他严重不良反应。结论硫普罗宁钠和还原型谷胱甘肽联合用于防治原发性肝癌TACE后肝损害效果显著,不良反应小,安全性高,值得临床推广应用。
Objective To observe the therapeutic effect of tiopronin combined with reduced glutathione on liver damage after primary hepatic artery chemoembolization (TACE). Methods Sixty-eight patients with hepatocellular carcinoma (HCC) after liver injury treated with TACE from March to December 2014 were randomly divided into treatment group (34 cases) and control group (34 cases). The treatment group was treated with tiopronin sodium combined with reduced glutathione, the control group with glucurolactone, inosine and other treatment, the clinical efficacy of two groups were observed before and after treatment of liver function and adverse reactions. Results After treatment, the indexes of liver function (ALT, AST, TBiL) in both groups were significantly improved (P <0.05), and the indexes in the treatment group were better than those in the control group (P <0.05). The total effective rate was 91.2% in the treatment group was significantly better than 65.7% in the control group, the difference was statistically significant (P <0.05). TEAC postoperative adverse reactions occurred in both groups, such as fatigue, nausea, vomiting, liver pain, fever, leukopenia, etc., but the improvement of the above symptoms in the treatment group than the control group. No other serious adverse reactions occurred during the two groups. Conclusion The combination of tiopronin sodium and reduced glutathione for the prevention and treatment of primary liver cancer after TACE has a significant effect on liver damage, with small adverse reactions and high safety. It is worthy of clinical application.